Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Frances Blevins, PA-C, David Hughes, PharmD, Charles Milrod, MD, Preya Patel, MD, Shayna DeMari, BA, Adam Lerner, MD, Shayna Sarosiek, MD, Vaishali Sanchorawala, MD, John Mark Sloan, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136775

Published: 2020

Journal Articles

Impact of Human T-Cell Lymphotropic Virus Infection on Survival Following Stem Cell Transplantation

Vishal K Gupta, MD, Areej El-Jawahri, MD, Murali Janakiram, MD, Mariam H Johnson, MPH, Janice Weinberg, PhD, Courtney B Goodrich, Grigori Okoev, MD PhD, John Mark Sloan, MD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-137347

Published: 2020

Journal Articles

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

David Hughes, PharmD, Radhika Jhaveri, PharmD, Bhavesh Shah, RPh, Frances Blevins, PA-C, Alexamil Rodriguez, CPhT, Shayna Sarosiek, MD, Adam Lerner, MD, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-135992

Published: 2020

Journal Articles

The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Vishal K Gupta, MD, Romy Carmen Lawrence, MD BS, Sarah L. Khan, Rachel Strykowski, MD, Brittany Scarpato, MD, Robyn T. Cohen, MD MPH, John Mark Sloan, MD, Elizabeth S Klings, MD

Blood (2019) 134 (Supplement_1): 2272.

https://doi.org/10.1182/blood-2019-122113

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Jose Acevedo, Gheorghe Doros, PhD, Raphael Szalat, John Mark Sloan, MD, Shayna Sarosiek, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 5447.

https://doi.org/10.1182/blood-2019-124980

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact

Radhika Jhaveri, PharmD, Vaishali Sanchorawala, MD, John Mark Sloan, MD, Adam Lerner, MD, Shayna Sarosiek, Bhavesh Shah, RPh

Blood (2019) 134 (Supplement_1): 4758.

https://doi.org/10.1182/blood-2019-128992

Published: 2019

Journal Articles

Patients with Sickle Cell Disease and Venous Thromboembolism Experience Increased Frequency of Vasoocclusive Events

Romy Carmen Lawrence, MD BS, Sarah L Khan, MD, Vishal Gupta, MD, Brittany Scarpato, MD, Rachel Strykowski, MD, Julia Newman, MD, John Mark Sloan, MD, Robyn T. Cohen, MD MPH, Seyed Mehdi Nouraie, PhD MD, Elizabeth S Klings, MD

Blood (2019) 134 (Supplement_1): 999.

https://doi.org/10.1182/blood-2019-122199

Published: 2019

Journal Articles

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

David Hughes, PharmD, Frances Blevins, PA-C, Bhavesh Shah, RPh, Shayna Sarosiek, Adam Lerner, MD, John Mark Sloan, MD

Blood (2019) 134 (Supplement_1): 4912.

https://doi.org/10.1182/blood-2019-124740

Published: 2019

Journal Articles

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2018) 132 (Supplement 1): 765.

https://doi.org/10.1182/blood-2018-99-118966

Published: 2018

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Vishal K Gupta, MD, Paul White, MD, Vaishali Sanchorawala, MD, Karen Quillen, MD MPH, Shayna Sarosiek, MD, Dina Brauneis, NP, John Mark Sloan, MD

Blood (2018) 132 (Supplement 1): 5738.

https://doi.org/10.1182/blood-2018-99-110230

Published: 2018

Journal Articles

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Vishal K Gupta, MD, Dina Brauneis, NP, Anthony C Shelton, RN, Karen Quillen, MD MPH, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2018) 132 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2018-99-111551

Published: 2018

Journal Articles

Recognizing the Existence of Heparin Induced Thrombocytopenia and Thrombosis in the Setting of High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Case Series

Shayna Sarosiek, MD, Karen Quillen, MDMPH, John Mark Sloan, MD, Dina Brauneis, NP, Vaishali Sanchorawala, MD

Blood (2017) 130 (Supplement 1): 3643.

https://doi.org/10.1182/blood.V130.Suppl_1.3643.3643

Published: 2017

Journal Articles

Brachial Plexopathy Following High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation for AL Amyloidosis

Vina Nguyen, MD, Dina Brauneis, NP, John Mark Sloan, MD, Shayna Sarosiek, MD, Karen Quillen, MD, Anthony C Shelton, RN, Vaishali Sanchorawala, MD

Blood (2017) 130 (Supplement 1): 5509.

https://doi.org/10.1182/blood.V130.Suppl_1.5509.5509

Published: 2017

Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2017) 130 (Supplement 1): 1298.

https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298

Published: 2017

Journal Articles

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Salli Fennessey, Anthony C Shelton, RN

Blood (2017) 130 (Supplement 1): 507.

https://doi.org/10.1182/blood.V130.Suppl_1.507.507

Published: 2017

Journal Articles

Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)

Michelle A. Fanale, MD, Steven I. Park, MD, David J. Valacer, MD, Jack Higgins, PhD, John Mark Sloan, MD, Anas Younes, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 5212.

https://doi.org/10.1182/blood.V130.Suppl_1.5212.5212

Published: 2017

Journal Articles

Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients

Robert Meehan, MD, David Seldin, MD, John Mark Sloan, MD, Karen Quillen, MD MPH, Dina Brauneis, ANP, Anthony C Shelton, RN, Vaishali Sanchorawala, MD

Blood (2014) 124 (21): 5906.

https://doi.org/10.1182/blood.V124.21.5906.5906

Published: 2014

Journal Articles

Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Stephen Lo, John Mark Sloan, MD, David C Seldin, MD PhD

Blood (2014) 124 (21): 3463.

https://doi.org/10.1182/blood.V124.21.3463.3463

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Impact of Human T-Cell Lymphotropic Virus Infection on Survival Following Stem Cell Transplantation

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact

Patients with Sickle Cell Disease and Venous Thromboembolism Experience Increased Frequency of Vasoocclusive Events

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Recognizing the Existence of Heparin Induced Thrombocytopenia and Thrombosis in the Setting of High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Case Series

Brachial Plexopathy Following High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation for AL Amyloidosis

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)

Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients

Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only